Summary & Overview
Other Infectious and Parasitic Diseases Diagnoses without CC/MCC: Inpatient Reimbursement Overview
DRG 869 groups inpatient stays for other infectious and parasitic disease diagnoses without a Major Complication or Comorbidity or a Complication or Comorbidity, reflecting lower-severity infection admissions. This grouping matters for inpatient reimbursement because it defines a bundled Medicare payment level that affects hospital revenue and resource allocation for these cases.
DRG 869 Overview
DRG 869 covers inpatient admissions for other infectious and parasitic disease diagnoses that do not include a Major Complication or Comorbidity or a Complication or Comorbidity. Typical cases include localized or systemic infections managed medically without high-severity comorbid conditions. This Diagnosis-Related Group matters for Medicare payment because it groups lower-severity infectious disease hospitalizations into a single payment category, influencing reimbursement and resource expectations for hospitals. Understanding this grouping helps clarify expected payment relative to higher-severity infectious disease Diagnosis-Related Groups.
Clinical Trials
- Acute antimicrobial optimization trials: randomized or pragmatic studies evaluating rapid diagnostic-guided antimicrobial selection and de-escalation strategies for hospitalized adults with diverse non-MCC infectious and parasitic diagnoses (for example bacteremia without organ failure, uncomplicated severe cellulitis, or parasitic enteritis). These studies enroll patients at admission or early inpatient stay to test whether rapid diagnostics and protocolized stewardship reduce antibiotic exposure, length of stay, and adverse events while maintaining clinical cure. Findings are directly relevant to hospital clinicians and payers because improved antimicrobial targeting can reduce inpatient resource use, drug costs, and readmissions for this heterogeneous DRG group.
- Comparative effectiveness studies of site-of-care and procedural management: observational cohorts or randomized trials comparing inpatient versus accelerated outpatient management pathways (including short-stay observation units, outpatient parenteral antimicrobial therapy, or early source-control procedures) for specific infections categorized in this DRG. These trials focus on subpopulations such as older adults with limited comorbidity burden, patients with localized abscesses, or parasitic infections requiring brief inpatient therapy, assessing outcomes like complications, rehospitalization, and total cost of care. For providers and payers, this research informs safe opportunities to shift care out of acute inpatient settings, optimizing reimbursement, bed utilization, and patient-centered outcomes.
- Post-discharge outcomes and health services research: longitudinal studies tracking functional recovery, infection recurrence, antibiotic-related adverse events, and healthcare utilization after hospitalization for other infectious/parasitic diagnoses without CC/MCC. These studies examine predictors of readmission, adherence to follow-up, and social determinants that influence recovery in a diverse population often discharged quickly but at risk for relapse or complications. Payers and care managers use this evidence to design targeted transitional care interventions, case management, and reimbursement models that reduce avoidable readmissions and downstream costs for this DRG cohort.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.